Loading data for LXRX — first visit, this takes a few seconds.

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqCM: LXRX · Real-Time Price · USD

2.19

-0.06 (-2.67%)

At close: Sep 08, 2026, 8:00 PM

2.25

+0.90%

After-hours: 6:06 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	1.92
Market Cap	992M
Revenue (ttm)	41.5M
Net Income (ttm)	-61.1M
	1.03
	-0.16
	n/a
	-11.7
P/B (ttm)	5.69
P/S (ttm)	23.93
Earnings Date	May 7, 2026

Ask	2.23
Volume	1,987,272
Avg. Volume (20D)	3,360,376
Open	2.24
Previous Close	2.25
Day's Range	2.17 - 2.27
52-Week Range	1.03 - 2.68
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 7, 2000

Employees 81

Stock Exchange NasdaqCM

Ticker Symbol LXRX

Website https://www.lexpharma.com

Full Company Profile

Financial Performance

In 2025, Lexicon Pharmaceuticals's revenue was 49.8M, an increase of 60.24% compared to the previous year's 31.08M. Earnings were -50.34M, a decrease of -74.88%.

Financial Statements

Earnings Surprise

Lexicon Pharmaceuticals has released their quarterly earnings on Aug 6, 2026:

Revenue of $692K misses estimates by $0, with -97.60% YoY decline.
EPS of -0.06 misses estimates by -0.01, with 14.29% YoY growth.

Next Earnings Release

Lexicon Pharmaceuticals, Inc. is scheduled to release its earnings on May 7, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 weeks ago · Stocktwits

LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon

Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.

2 weeks ago · Simply Wall St.

Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone

Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development of first in class oral obesity drug LX9851. Lexicon received a milestone payment from Novo Nordisk tie...

3 weeks ago · Motley Fool

Lexicon (LXRX) Q2 2026 Earnings Call Transcript

SONATA-HCM Phase III enrollment topped 500 patients; data due Q1 2027.

1 month ago · Simply Wall St.

Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings

In early August 2026, Lexicon Pharmaceuticals reported second-quarter results showing revenue of US$692,000 versus US$28.87 million a year earlier, alongside a shift from net income of US$3.25 million...

1 month ago · GuruFocus.com

Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ...

Lexicon Pharmaceuticals Inc (LXRX) advances its pipeline with strong cash position despite a challenging quarter marked by a net loss and reduced revenues.

Page 1 of 2

Lexicon Pharmaceuticals, Inc. (LXRX)